Track topics on Twitter Track topics that are important to you
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner updates Proactive Investors on the latest developments with the Texas-based company's non-small cell lung cancer drug, including positive study results done in humanized mice.
Varner says the study of its lead drug Oncoprex at The University of Texas MD Anderson Cancer Center was completed in April after examining the effects of the tumor suppressor gene TUSC2 found in Oncoprex in combination with immunotherapy treatment.
Original Article: Genprex updates on positive results for its lung cancer drug OncoprexNEXT ARTICLE
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...